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Preface
Epidemic inﬂuenzaviruses remainhigh on the listof the infectious
agents that inﬂict signiﬁcant morbidity and mortality on the
human population. The recent and ongoing outbreak of ‘swine
ﬂu’ provides a timely reminder of how rapidly new strains can
emerge, and this family of viruses continues to pose the real
threat of a catastrophic pandemic. Much effort is rightly directed
todeveloping bettermethodsforprotectivevaccination,but inﬂu-
enzavirusisgeneticallymobileandantiviralcompoundsalsohave
an important role in our defensive strategy.
Thehistoryofanti-inﬂuenzachemotherapydatesbackto1964
with the discovery of amantadine and subsequently rimantadine.
These compounds proved the principle that inﬂuenza therapy
could prevent or ameliorate the clinical signs in this highly infec-
tious acute disease. However, those early compounds enjoyed
only limited success, and this lack of efﬁcacy was, at least in
part, thought to be due to the rapid selection of amantadine-
resistant variants. Structural studies on inﬂuenza virion com-
ponents, in particular the envelope glycoproteins, enabled the
rationaldesignofneuraminidaseinhibitorsstartingwithzanamivir
in 1993. Zanamivir was an important breakthrough; however, its
utility is limited by poor oral bioavailability. The ﬁrst report in
1997 of oseltamivir (Tamiﬂu), a neuraminidase inhibitor oral
prodrug that overcame this limitation, thus represented another
major advance in the ﬁeld.
The recent ﬂu pandemic has once more provided urgency
for the development and assessment of inﬂuenza antiviral
chemotherapy. During the last decade a great deal of valuable
data have been obtained from the use of oseltamivir in different
human populations under various circumstances, including infor-
mation on the signiﬁcant problem of antiviral resistance. This
Supplement rehearses many of the key ﬁndings from the clinical
trials to date. The scholarly reviews are by four authors who are
all international experts with direct experience of oseltamivir. As
well as providing some insight into current and planned lines of
investigation, the conclusions they draw will help to inform
debate on the further use of oseltamivir. Furthermore, the
articles should provide an important source of background infor-
mation to enlighten trials with future novel inﬂuenza antiviral
compounds.
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